| 产品名称 | 
 Recombinant Cynomolgus PD-L1 (C-Fc)  | 
| 英文名称 | 
 PD-L1/B7-H1/CD274/Programmed Cell Death 1 Ligand 1  | 
| 纯度 | 
 Greater than 95% as determined by reducing SDS-PAGE  | 
| 内毒素 | 
 <1 EU/µg as determined by LAL test.  | 
| 蛋白构建 | 
 Recombinant Cynomolgus CD274 Molecule is produced by our Mammalian expression system and the target gene encoding Phe19-Thr239 is expressed with a human IgG1 Fc tag at the C-terminus.  | 
| Accession | 
 G7PSE7  | 
| 表达宿主 | 
 Human Cells  | 
| 种属 | 
 Cynomolgus  | 
| 预测分子量 | 
 52.4 KDa  | 
| 制剂 | 
 Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.  | 
| 运输方式 | 
 The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.  | 
| 稳定性&储存 | 
 Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.  | 
| 复溶 | 
 Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.  | 
| 分子别名 | 
| B7-H; B7H1; B7-H1; B7H1PDCD1L1; CD274 antigenMGC142294; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1 | 
| 背景介绍 | 
| CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers. | 
注意事项
本司产品仅用于科研,不用于临床诊断和治疗